RecruitingPhase 3NCT05611801
Blood
Moderate hemophilia A
8
studies recruiting now
as of 7 Sept 2026
77
studies registered in total
as of 7 Sept 2026
26
countries with a recruiting site
as of 7 Sept 2026
10 Nov 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1 / Phase 2NCT06379789
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RecruitingPhase 1 / Phase 2NCT07226206
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RecruitingPhase 1 / Phase 2NCT05987449
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RecruitingNCT05022459
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 8 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Moderate hemophilia A study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Moderate hemophilia A
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (F8).
Treatments being studied
20 approved treatments and 15 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Damoctocog Alfa Pegol (Jivi)Approved: Susoctocog Alfa (Obizur)Approved: Marstacimab (Hympavzi)Approved: Turoctocog Alfa Pegol (Esperoct)Approved: Efmoroctocog Alfa (Elocta)Approved: Valoctocogene Roxaparvovec (Roctavian)Approved: Concizumab (Alhemo)Approved: Emicizumab (Hemlibra)Approved: Moroctocog Alfa (Refacto af)Approved: Human Coagulation Factor Viii (Hemofil m)Approved: Eptacog Beta (Activated) (Cevenfacta)Approved: Von Willebrand Factor Human (Von willebrand factor human component of voncento)Approved: Simoctocog Alfa (Nuwiq)Approved: Turoctocog Alfa (Novoeight)Approved: Antihemophilic Factor, Pegylated (Mw 20000) Human Sequence Recombinant (Adynovi)Approved: Tranexamic Acid (Cyklo-f heavy period relief)Approved: Efanesoctocog Alfa (Altuviiio)Approved: Eptacog Alfa (Activated) (Novoseven)Approved: Octocog Alfa (Advate)Approved: Lonoctocog Alfa (Afstyla)
Phase 3Denecimig
Phase 3Giroctocogene Fitelparvovec
Phase 3Fitusiran
Phase 3Anti-Inhibitor Coagulant Complex
Phase 3Vatreptacog Alfa (Activated)
Phase 3Omfiloctocog Alfa
Phase 2/3Thrombin
Phase 2Ataluren (Translarna)
+ 7 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).